The 2022 Weston Lecture: Ahmara Gibbons Ross, MD, PhD
“Neuroprotection: A New Path for Glaucoma Patients” was the topic of the 2022 Weston Family Lecture presented virtually on October 27, 2022.
Menu
Menu
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
“Neuroprotection: A New Path for Glaucoma Patients” was the topic of the 2022 Weston Family Lecture presented virtually on October 27, 2022.
This one-hour recorded webinar was first presented on October 14, 2022 by Glaucoma Research Foundation.
Whether you’ve recently been diagnosed with glaucoma or are learning how to cope, connecting with others can be helpful and powerful.
Assistive devices and technology can help people with low vision and vision loss to participate in daily activities with minimal impairment.
Contrast sensitivity is the eyes’ ability to identify an object not clearly defined from its background.
If your child has glaucoma or a child in your classroom has it, you may wonder how the condition affects their ability to learn in school.
The new glaucoma eye drop medication increases drainage through the eye’s conventional outflow pathways via a unique pharmacological action.
Although no studies prove a connection between specific foods and glaucoma, it’s safe to assume that your diet and your overall health can affect the disease.
If you are experiencing side effects from your glaucoma medications, learn what you can do to reduce or eliminate them.
Made possible by visionary donors, our latest research initiative targets the shared roots of conditions that occur when neurons deteriorate and die.
The Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration will support creative collaboration by a team of four diversely talented young investigators.
The Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration is the inspiration of longtime GRF supporters Ted and Melza Barr.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2022 all rights reserved.
Print Subscription
(The printed edition of the Gleams newsletter is only available if you live in the United States or Canada)
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
E-mail Subscription
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.